Artikelen

Nutrition and nutrients and effect on liver cancer: Menatetrenone (= analog in vitamin K2) reduces the chances of a relapse in operable rectal liver cancer significant-42.7% after 1 year and 27.3% after 3 years) and 3 year survival with 23% improves. New meta-analysis confirms results. Article update 15 October 2011

October 15th, 2011: abstract of a later study at the bottom I have to effect of menatetrenone (vitamin K2) in liver tumours. With the same positive results as from the following study shows from March 2006.

22 March 2006: Source: SOURCE: Cancer 2006; 106:867-872

Menatetrenone (= analog in vitamin K2) reduces to the probability of an operable rectal liver cancer relapse after 1 year significantly with 42.7% and 27.3% and improves 3 year after three years with 23% survival. We translate for you the complete press release of Reuters about this study.

Menatetrenone significantly improves liver cancer treatments

NEW YORK (Reuters Health)-MAT 16, 2006 For patients undergoing curative treatment-healing for their liver cancer (HCC) have gotten reduces menatetrenone (analogous to a drug vitamin K2) recurrences and significantly improves survival, thus showing the results from a randomized pilot study.

Menatetrenone is an analogue of vitamin K2, which demonstrated earlier against leukemia and liver cell lines to give antiproliferatieve effects explain the authors.

Dr. Toshihiko Nagamatsu and colleagues of the Saga Medical School, Japan, investigated the effects of menatetrenone (analogous to vitamin K2) of return of disease and survival in 61 patients with HCC primary liver cancer surgery or percutaneous local ablation therapy, which (TACE and/or RFA) had had.

Then the relapse of HCC in the acting group was 12.5% after 12 months, menatetrenone 39.0% after 24 months, and 64.3% after 36 months, compared with 55.2%, 83.2% and 91.6%, respectively, in the placebo group, said the authors.

The ultimate survival rates were also significantly higher in the group than in the placebo group menatetrenone (100% versus 96.4% after 12 months, 96.6% vs. 80.9% after 24 months, and 87.0% versus 64% after 36 months), reports the study report.

Menatetrenone administration was not associated with side effects, researchers report in the February 15 Edition of Cancer and no patient with the study stopped during the follow-up period of study of median 28.9 months Menatetrenone (beneficial) for patients was effectively independent of the basic values of des-gamma-carboxy prothrombin-(a possible marker of aggressive tumors which are suppressed by the administration of vitamin K2), show the results. "The results of this randomized pilot study shows that the possible risk of a relapse of menatetrenone HCC liver cancer after operation or local ablative surgery lessens," conclude the authors. "The effect on survival requires further studies; However, all in all, chemo-prevention of a relapse of HCC-liver cancer by use of menatetrenone-vit. K2 seems to be a promising option ".

SOURCE: Cancer 2006; 106:867-872.

Hepatocellular Carcinoma Menatetrenone Improves Outcome

NEW YORK MAT 16, 2006(Reuters Health)-For patients who have received treatment for hepatocellular carcinoma (HCC), curative menatetrenone reduces recurrences and improves survival, the results of a pilot study suggest.

Is an analog of vitamin K2, Menatetrenone which has been shown to have leukemia and antiproliferative effects against hepatoma cell lines, the authors explain. Dr. Toshihiko Nagamatsu and colleagues from Saga Medical School, Japan, investigated the effects of menatetrenone on disease recurrence and survival in 61 patients with HCC after they underwent percutaneous local ablation therapy curative resection or.

The cumulative incidence of HCC recurrence in the group was 12.5% at 12 months, menatetrenone 39.0% at 24 months, 36 months, 64.3% and at the authors report, compared with 55.2%, 91.6%, respectively, 83.2%, and in the placebo group. Survival rates were also higher in the group than in the placebo group menatetrenone (100% versus 96.4% at 12 months, 24 months, 96.6% vs. 80.9% at 87.0% versus 64% at 36 months and), the report indicates. Menatetrenone treatment was not associated with any adverse effects, the researchers report in the February 15th issue of Cancer, and no patient was withdrawn from the study during an average 28.9 months of follow-up. Menatetrenone was beneficial in patients regardless of the baseline level of des-gamma-carboxy prothrombin-(a possible marker or more aggressive tumors that is suppressed by vitamin K2 administration), the results indicate. "The results from this randomized, controlled, pilot study revealed that may reduce the risk of HCC recurrence menatetrenone possibly after curative surgical resection or local ablation therapy," the authors conclude. "The effect on survival warrants further research; however, overall, chemo-prevention of secondary menatetrenone appears to be a promising HCC using option. "

SOURCE: Cancer 2006; 106:867-872.

Hepatocellular carcinoma after chemo-prevention of Vitamin analogues in resection or ablation--a systematic review and meta-analysis

Hepatocellular carcinoma after chemo-prevention of Vitamin analogues in resection or ablation--a systematic review and meta-analysis.

RESULTS:

Oral retinoids (vitamin A analogue) administration of acyclic, menatetrenone (vitamin K2 analogue) and have been tested as chemopreventive agents after hepatic resection or local ablative therapy for HCC. There were randomised, controlled trials one and four (RCTs) which evaluated the efficacy or polyprenoic acid and menatetrenone, respectively. All studies were conducted in Japan. One RCT showed the preventive effect or polyprenoic acid in lowering the incidence of HCC recurrence after hepatic resection or percutaneous ethanol injection, and this effect lasted up to 199 weeks after randomization (or 151 weeks after completion or retinoid administration). Four RCTs evaluated the preventive efficacy of recurrence after hepatic resection menatetrenone on HCC or local ablative therapy. The results of three studies, as well as the meta-analysis of all four studies, showed significantly better tumour recurrence-free survival. The beneficial effect on the overall survival was less definite.

CONCLUSION:

There is evidence to suggest that partial or local ablative therapy chemopreventive therapy after hepatectomy is beneficial in prolonging disease-free survival, but the evidence is less for an effect on the overall survival. To confirm the beneficial role of vitamin A or K analogues in the chemo-prevention of HCC further and larger randomised trials are now required.

Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.